| Autor: |
Wirth LJ; Massachusetts General Hospital, Boston, MA., Brose MS; University of Pennsylvania, Philadelphia, PA., Subbiah V; University of Texas MD Anderson Cancer Center, Houston, TX.; Sarah Cannon Research Institute, Nashville, TN., Worden F; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Solomon B; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Robinson B; Royal North Shore Hospital, St Leonards, NSW, Australia., Hadoux J; Service d'Oncologie Endocrinienne, Gustave Roussy, Villejuif, France., Tomasini P; Aix-Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, Marseille, France., Weiler D; Cantonal Hospital, Luzern, Switzerland., Deschler-Baier B; University of Würzburg Comprehensive Cancer Centre, Würzburg, Germany., Tan DSW; National Cancer Centre Singapore, Singapore.; Duke-NUS Medical School, Singapore., Maeda P; Eli Lilly and Company, Indianapolis, IN., Lin Y; Eli Lilly and Company, Indianapolis, IN., Singh R; Eli Lilly and Company, Indianapolis, IN., Bayt T; Eli Lilly and Company, Indianapolis, IN., Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Cassier PA; Centre Léon Bérard, Medical Oncology, Lyon, France. |
| Abstrakt: |
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. LIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib in patients with RET (REarranged during Transfection)-activated cancers (ClinicalTrials.gov identifier: NCT03157128). We present long-term safety and efficacy from LIBRETTO-001 in patients with RET -mutant medullary thyroid cancer (MTC; n = 324) and RET fusion-positive thyroid cancer encompassing different histological subtypes (TC; n = 66). At the data cutoff of January 2023, the objective response rate was 82.5% among patients with cabozantinib/vandetanib-naïve MTC and 95.8% among patients with treatment-naïve TC. At a median follow-up time of 42.4 and 44.0 months in patients with cabozantinib/vandetanib-naïve and pretreated MTC, the median progression-free survival (PFS) was not reached and 41.4 months, respectively. At a median follow-up time of 24.9 and 30.4 months in patients with treatment-naïve and pretreated TC, the median PFS was not reached and 27.4 months, respectively. Three-year PFS rates were 75.2% and 87.3% among patients with cabozantinib/vandetanib-naïve MTC and treatment-naïve TC, respectively. Median PFS was similar to median duration of response for each patient group. The safety profile of selpercatinib was consistent with previous reports. With an additional follow-up of 37 months and 228 more patients from the last disclosure, selpercatinib continued to provide durable and robust responses in treatment-naïve and previously treated patients with RET -mutant MTC and RET fusion-positive TC. |
